GSK Launches Plus Reduced Generic Exposure Will Boost U.S. Sales Ahead, Says CEO Witty
This article was originally published in The Pink Sheet Daily
Executive Summary
Products currently pending at FDA include Cervarix vaccine, Rezonic anti-emetic, Lamictal XR for epilepsy and Duodart fixed-dose combo.
You may also be interested in...
GSK Temporarily Pulls sNDA For Avodart
GSK has temporarily pulled its supplemental application for Avodart for reducing the risk of prostate cancer, in order to update the data in the sNDA.
GSK Temporarily Pulls sNDA For Avodart
GSK has temporarily pulled its supplemental application for Avodart for reducing the risk of prostate cancer, in order to update the data in the sNDA.
Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B
News on melanoma could put the biotech’s lucrative partnership with GlaxoSmithKline in jeopardy.